

Oncology with GCCL

Main Issue in Oncology market



AMTAGVI™ (lifileucel) Suspension for IV infusion

In February 2024 FDA granted accelerated approval to 'AMTAGVI', the first cell therapy for solid tumors



Keytruda® (pembrolizumab)

As of 2023 ranked as the top global revenue earner
*patent expiration in 2028

Biomarker analysis services

- ▶ Commercial(RUO) Kit (incl. Simoa, MSD, Luminox, etc.)
- ▶ Assay Development & Analysis (Lab Development Test)



GCCL@gccorp.com

Inquiries

031-270-1381

www.gccl.co.kr

Oncology stands as the foremost field for clinical trial approvals annually, with numerous vaccines and treatments currently in development. The cancer treatment market is poised for significant growth, projected to expand by an annual average rate of 7.6% by 2030, with more than 2000 treatments currently being developed.

GCCL possesses extensive experience in analyzing clinical trial samples within the field of oncology, providing us with a high level of expertise. GCCL stands as a trusted partner for clients, offering our expertise in analysis, a cutting-edge analysis platform, and customized project management services.

GCCL's Service for Oncology analysis

✓ Analytical Service

- PK analysis
- PD analysis
- Biomarker analysis
- FACS analysis
- Genomic analysis
- Safety Test

✓ Sample Processing & Storage

- PBMC Isolation
- Nucleic Acid extraction
- Study Sample Storage

✓ Project Mangement

- Lab kit preparation & G-HUB

✓ Analytical Platform

- MSD
- Lyric
- QX one

Fact Sheet in GCCL's Oncology

39%


Experience for
Oncology
in Biopharmaceuticals

FDA


The anticancer drug analyzed by
GCCL has been designated
as an **Orphan drug**

By Cancer Type

Recent 3 years (2021 ~ 2023)



by Indication of Solid Tumor



• Ovarian cancer, Prostate cancer, Head and Neck cancer, etc.

by Modality of Solid Tumor

